Dose-Finding, Safety, Pharmacokinetic and Pharmacodynamic Study of AVE1642, an Anti-Insulin-Like Growth Factor-1 Receptor (IGF-1R/CD221) Monoclonal Antibody, Administered as Single Agent and in Combination With Other Anti Cancer Therapies (Sorafenib or Erlotinib) in Patients With Advanced Liver Carcinoma.
Phase of Trial: Phase I/II
Latest Information Update: 25 Apr 2014
At a glance
- Drugs AVE 1642 (Primary) ; Erlotinib; Sorafenib
- Indications Liver cancer
- Focus Adverse reactions
- Sponsors Sanofi
- 09 Dec 2009 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
- 21 Oct 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 28 Nov 2008 New trial record.